A Demonstration of the Hair and Scalp Benefits of Duobrii in Scalp Psoriasis

Scalp Psoriasis Clinical Trial

Official title:

A Demonstration of the Hair and Scalp Benefits of 0.045% Tazarotene/0.01% Halobetasol Lotion in Scalp Psoriasis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05872256
• Other study ID #: DCS-165-22
• Status: Completed
• Phase: Phase 4
• Start date: June 1, 2023
• Est. completion date: November 13, 2023

Study information

• Verified date: November 2023
• Source: Dermatology Consulting Services, PLLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objectives of this research are to demonstrate the following:1. To demonstrate improvement in hair growth and hair appearance following 12 weeks of once daily treatment with tazarotene/halobetasol lotion in patients with moderate to severe scalp psoriasis.2. To demonstrate improvement in scalp itch reduction following 12 weeks of once daily treatment with tazarotene/halobetasol lotion in patients with moderate to severe scalp psoriasis.3. To pictorially demonstrate improvement in moderate to severe scalp psoriasis with 12 weeks of once daily treatment with tazarotene/halobetasol lotion.4. To assessment patient perceptions of the value of a lotion in the treatment of moderate to severe scalp psoriasis.

Description:

Male or female subjects with moderate to severe scalp psoriasis will present to the research center for evaluation for study entry. They will have been advised to present to the research center with clean hair and no topical products applied to the scalp. If found to be suitable by meeting all inclusion criteria and none of the exclusion criteria, subjects will undergo scalp psoriasis evaluation by the dermatologist investigator for erythema, scaling, and induration. The subjects will also assess each plaque for redness, thickness, and scaling. The subjects and the dermatologist will assess the hair for lack of hair shine, poor manageability, frizziness, poor hair color, poor hair growth, and damaged cuticle structure. The subjects will assess scalp itch. Finally, digital photography will be conducted of the scalp psoriasis.Each subject will be dispensed one tube of tazarotene/halobetasol lotion for application to scalp once daily. Subjects will be provided with a diary. Subjects will be instructed to return to the research center in 4 weeks. A reminder text for compliance will be provided prior to the week 4 visit and for all return visits.Subjects will return to the research center at week 4 and week 8 and week 12 for the same assessments. At week 12, a consumer perception survey will also be administered. All diaries will be collected at week 12. Subjects will be allowed to keep any unused study product. Subjects will complete their study participation at week 12.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: November 13, 2023
• Est. primary completion date: November 13, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 1. Males or non-pregnant females 18+ years of age. 2. Plaque type moderate to severe scalp psoriasis suitable for topical treatment.

3. Subjects must be in general good health as determined from a medical history.

4. Subjects must read and sign the informed consent form after the nature of the study has been fully explained.

Exclusion Criteria:

• 1. Subjects with known allergies or sensitivities to ingredients contained in the test products.

2. Subjects with pustular or erythrodermic psoriasis. 3. Subjects who are pregnant or nursing or planning to become pregnant during the course of the study.

4. Subjects who are currently participating in any other clinical study (i.e., dermal patch, use tests, investigational drug or devices, etc.).

5. Subjects viewed by the investigator as not being able to complete the study. 6. Subjects using any type of lotion, medication, or other topical product to the scalp psoriasis within 2 weeks of study entry.

Related Conditions & MeSH terms

• Psoriasis
• Scalp Psoriasis

Intervention

Drug:
• 0.045% Tazarotene/0.01% Halobetasol Lotion
FDA approved drug for psoriasis treatment

Locations

Country	Name	City	State
United States	Dermatology Consulting Services, PLLC	High Point	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
Dermatology Consulting Services, PLLC	Ortho Dermatologics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Hair Growth	Improvement in hair growth due to scalp psoriasis treatment	12 weeks
Primary	Scalp Itch	Reduction in scalp itch due to scalp psoriasis treatment	12 weeks